Literature DB >> 28922577

Functional N-Formyl Peptide Receptor 2 (FPR2) Antagonists Based on the Ureidopropanamide Scaffold Have Potential To Protect Against Inflammation-Associated Oxidative Stress.

Madia L Stama1, Enza Lacivita1, Liliya N Kirpotina2, Mauro Niso1, Roberto Perrone1, Igor A Schepetkin2, Mark T Quinn2, Marcello Leopoldo1.   

Abstract

Formyl peptide receptor 2 (FPR2) is a G protein coupled receptor belonging to the N-formyl peptide receptor (FPR) family that plays critical roles in peripheral and brain inflammatory responses. FPR2 has been proposed as a target for the development of drugs that could facilitate the resolution of chronic inflammatory reactions by enhancing endogenous anti-inflammation systems. Starting from lead compounds previously identified in our laboratories, we designed a new series of ureidopropanamide derivatives with the goal of converting functional activity from agonism into antagonism and to develop new FPR2 antagonists. Although none of the compounds behaved as antagonists, some of the compounds were able to induce receptor desensitization and, thus, functionally behaved as antagonists. Evaluation of these compounds in an in vitro model of neuroinflammation showed that they decreased the production of reactive oxygen species in mouse microglial N9 cells after stimulation with lipopolysaccharide. These FPR2 ligands may protect cells from damage due to inflammation-associated oxidative stress.
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  antagonists; inflammation; oxidative stress; receptors; ureidopropanamide

Mesh:

Substances:

Year:  2017        PMID: 28922577      PMCID: PMC5909973          DOI: 10.1002/cmdc.201700429

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  51 in total

Review 1.  Sources and targets of reactive oxygen species in synaptic plasticity and memory.

Authors:  Kenneth T Kishida; Eric Klann
Journal:  Antioxid Redox Signal       Date:  2007-02       Impact factor: 8.401

2.  Decomposition of reactive oxygen species by copper(II) bis(1-pyrazolyl)methane complexes.

Authors:  Igor Schepetkin; Andrei Potapov; Andrei Khlebnikov; Elena Korotkova; Anna Lukina; Galina Malovichko; Lilia Kirpotina; Mark T Quinn
Journal:  J Biol Inorg Chem       Date:  2006-04-22       Impact factor: 3.358

3.  Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer.

Authors:  Amalia Azzariti; Nicola A Colabufo; Francesco Berardi; Letizia Porcelli; Mauro Niso; Grazia M Simone; Roberto Perrone; Angelo Paradiso
Journal:  Mol Cancer Ther       Date:  2006-07       Impact factor: 6.261

Review 4.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

5.  Lewis Basic Sulfide Catalyzed Electrophilic Bromocyclization of Cyclopropylmethyl Amide.

Authors:  Ying-Chieh Wong; Zhihai Ke; Ying-Yeung Yeung
Journal:  Org Lett       Date:  2015-10-06       Impact factor: 6.005

6.  Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1.

Authors:  Caihong Zhou; Song Zhang; Masakatsu Nanamori; Yueyun Zhang; Qing Liu; Na Li; Meiling Sun; Jun Tian; Patrick P Ye; Ni Cheng; Richard D Ye; Ming-Wei Wang
Journal:  Mol Pharmacol       Date:  2007-07-25       Impact factor: 4.436

Review 7.  Resolution of inflammation: state of the art, definitions and terms.

Authors:  Charles N Serhan; Sue D Brain; Christopher D Buckley; Derek W Gilroy; Christopher Haslett; Luke A J O'Neill; Mauro Perretti; Adriano G Rossi; John L Wallace
Journal:  FASEB J       Date:  2007-02       Impact factor: 5.191

8.  The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine.

Authors:  John R Hornick; Jinbin Xu; Suwanna Vangveravong; Zhude Tu; Jonathan B Mitchem; Dirk Spitzer; Peter Goedegebuure; Robert H Mach; William G Hawkins
Journal:  Mol Cancer       Date:  2010-11-22       Impact factor: 27.401

9.  Formylpeptide Receptors Promote the Migration and Differentiation of Rat Neural Stem Cells.

Authors:  Guan Wang; Liang Zhang; Xingxing Chen; Xin Xue; Qiaonan Guo; Mingyong Liu; Jianhua Zhao
Journal:  Sci Rep       Date:  2016-05-13       Impact factor: 4.379

10.  Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals.

Authors:  Charles N Serhan; Song Hong; Karsten Gronert; Sean P Colgan; Pallavi R Devchand; Gudrun Mirick; Rose-Laure Moussignac
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

View more
  3 in total

1.  Pyridazinones and Structurally Related Derivatives with Anti-Inflammatory Activity.

Authors:  Niccolo Cantini; Igor A Schepetkin; Nadezhda V Danilenko; Andrei I Khlebnikov; Letizia Crocetti; Maria Paola Giovannoni; Liliya N Kirpotina; Mark T Quinn
Journal:  Molecules       Date:  2022-06-10       Impact factor: 4.927

2.  Formyl Peptide Receptor 2 Activation Ameliorates Dermal Fibrosis and Inflammation in Bleomycin-Induced Scleroderma.

Authors:  Gyu Tae Park; Yang Woo Kwon; Tae Wook Lee; Seong Gyu Kwon; Hyun-Chang Ko; Moon Bum Kim; Jae Ho Kim
Journal:  Front Immunol       Date:  2019-09-03       Impact factor: 7.561

3.  Identification and validation of a prognostic signature and combination drug therapy for immunotherapy of head and neck squamous cell carcinoma.

Authors:  Weijie Qiang; Yifei Dai; Xiaoyan Xing; Xiaobo Sun
Journal:  Comput Struct Biotechnol J       Date:  2021-02-09       Impact factor: 7.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.